[HTML][HTML] Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)
BO Roep, S Thomaidou, R van Tienhoven… - Nature Reviews …, 2021 - nature.com
Type 1 diabetes mellitus is believed to result from destruction of the insulin-producing β-cells
in pancreatic islets that is mediated by autoimmune mechanisms. The classic view is that …
in pancreatic islets that is mediated by autoimmune mechanisms. The classic view is that …
The pathogenic “symphony” in type 1 diabetes: A disorder of the immune system, β cells, and exocrine pancreas
MA Atkinson, RG Mirmira - Cell Metabolism, 2023 - cell.com
Summary Type 1 diabetes (T1D) is widely considered to result from the autoimmune
destruction of insulin-producing β cells. This concept has been a central tenet for decades of …
destruction of insulin-producing β cells. This concept has been a central tenet for decades of …
The heterogeneous pathogenesis of type 1 diabetes mellitus
J Ilonen, J Lempainen, R Veijola - Nature Reviews Endocrinology, 2019 - nature.com
Type 1 diabetes mellitus (T1DM) results from the destruction of pancreatic β-cells that is
mediated by the immune system. Multiple genetic and environmental factors found in …
mediated by the immune system. Multiple genetic and environmental factors found in …
[HTML][HTML] Role of polyamines and hypusine in β cells and diabetes pathogenesis
The polyamines—putrescine, spermidine, and spermine—are polycationic, low molecular
weight amines with cellular functions primarily related to mRNA translation and cell …
weight amines with cellular functions primarily related to mRNA translation and cell …
T cell–mediated autoimmunity in immune thrombocytopenia
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet
count and an increased risk of bleeding. In addition to anti‐platelet autoantibodies, CD8+ T …
count and an increased risk of bleeding. In addition to anti‐platelet autoantibodies, CD8+ T …
[HTML][HTML] Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic β cells
D Neiman, D Gillis, S Piyanzin, D Cohen, O Fridlich… - JCI insight, 2020 - ncbi.nlm.nih.gov
It has been proposed that unmethylated insulin promoter fragments in plasma derive
exclusively from β cells, reflect their recent demise, and can be used to assess β cell …
exclusively from β cells, reflect their recent demise, and can be used to assess β cell …
[HTML][HTML] How curcumin targets inflammatory mediators in diabetes: therapeutic insights and possible solutions
Diabetes mellitus is a multifactorial chronic metabolic disorder, characterized by altered
metabolism of macro-nutrients, such as fats, proteins, and carbohydrates. Diabetic …
metabolism of macro-nutrients, such as fats, proteins, and carbohydrates. Diabetic …
Islet‐specific CD8+ T cells gain effector function in the gut lymphoid tissues via bystander activation not molecular mimicry
M Okada, V Zhang, JD Loaiza Naranjo… - … and Cell Biology, 2023 - Wiley Online Library
Abstract Type 1 diabetes (T1D) is caused by aberrant activation of autoreactive T cells
specific for the islet beta cells. How islet‐specific T cells evade tolerance to become effector …
specific for the islet beta cells. How islet‐specific T cells evade tolerance to become effector …
Proinsulin C-peptide is an autoantigen in people with type 1 diabetes
M So, CM Elso, E Tresoldi, M Pakusch… - Proceedings of the …, 2018 - National Acad Sciences
Type 1 diabetes (T1D) is an autoimmune disease in which insulin-producing beta cells,
found within the islets of Langerhans in the pancreas, are destroyed by islet-infiltrating T …
found within the islets of Langerhans in the pancreas, are destroyed by islet-infiltrating T …
Immune mechanisms and pathways targeted in type 1 diabetes
LM Jacobsen, BN Newby, DJ Perry, AL Posgai… - Current diabetes …, 2018 - Springer
Abstract Purpose of Review The immunosuppressive agent cyclosporine was first reported
to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 …
to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 …